Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05548270 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of DPI-386 Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion
A Phase 3 study, sponsored by Repurposed Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 503
- Enrollment target
NCT05548270 is a Phase 3 study that has completed, run by Repurposed Therapeutics. The registered enrollment target is 503 participants.
The verdict
NCT05548270, a Phase 3 study, has completed, sponsored by Repurposed Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 503 participants
- Enrollment target
Study Summary
This is a Phase 3, randomized, double-blind, placebo-controlled study evaluating DPI-386 Nasal Gel versus placebo. Approximately 500 subjects will be randomized 1:1 (250 DPI 386 Nasal Gel/250 matching Placebo Nasal Gel) are planned to be enrolled.
Interventions
- DRUG Placebo
- DRUG DPI-386 Nasal Gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 503 participants |
| Start Date | 2022-08-23 |
| Est. Completion | 2022-11-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05548270
The ClinicalTrials.gov registry entry for NCT05548270 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 503 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Repurposed Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05548270 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05548270 about?
NCT05548270 is a clinical study titled "Efficacy and Safety of DPI-386 Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion". This is a Phase 3, randomized, double-blind, placebo-controlled study evaluating DPI-386 Nasal Gel versus placebo. Approximately 500 subjects will be randomized 1:1 (250 DPI 386 Nasal Gel/250 matching Placebo Nasal Gel) are planned to be enrolled.
What is the current status of trial NCT05548270?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 503 participants. The study started on 2022-08-23. Estimated completion is 2022-11-29.
What interventions are being tested in trial NCT05548270?
The interventions under investigation include: Placebo (DRUG), DPI-386 Nasal Gel (DRUG).
Who is sponsoring clinical trial NCT05548270?
This trial is sponsored by Repurposed Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.